MicroRNA profiling in canine multicentric lymphoma

• Published in: PloS one 2019-12, Vol.14 (12), p.e0226357-e0226357
• Main Authors: Craig, Karlee K L, Wood, Geoffrey A, Keller, Stefan M, Mutsaers, Anthony J, Wood, R Darren
• Format: Article
• Language: English
• Subjects: Animals; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; B-cell lymphoma; Biology and life sciences; Biomarkers; Biomarkers, Tumor - genetics; Biomarkers, Tumor - metabolism; Cancer; Cancer therapies; Chemotherapy; Classification; Comparative analysis; Consent; Cyclophosphamide - therapeutic use; Diagnosis; Dog Diseases - diagnosis; Dog Diseases - drug therapy; Dog Diseases - genetics; Dog Diseases - mortality; Dogs; Doxorubicin - therapeutic use; Ethylenediaminetetraacetic acid; Female; Gene expression; Gene Expression Regulation, Neoplastic; Gene regulation; Genes; Genetic aspects; Genetic transcription; Health aspects; Immunophenotyping; Kaplan-Meier Estimate; Lymph nodes; Lymph Nodes - metabolism; Lymphatic system; Lymphocytes; Lymphocytes T; Lymphoma; Lymphoma, B-Cell - diagnosis; Lymphoma, B-Cell - drug therapy; Lymphoma, B-Cell - genetics; Lymphoma, B-Cell - mortality; Lymphoma, T-Cell - diagnosis; Lymphoma, T-Cell - drug therapy; Lymphoma, T-Cell - genetics; Lymphoma, T-Cell - mortality; Male; Medical diagnosis; Medical prognosis; Medicine and Health Sciences; MicroRNA; MicroRNAs; MicroRNAs - blood; MicroRNAs - metabolism; miRNA; Neoplasm Recurrence, Local; Nodes; Non-Hodgkin's lymphomas; Post-transcription; Predictions; Prednisone - therapeutic use; Prognosis; Progression-Free Survival; Remission; Ribonucleic acid; RNA; Survival; T cells; T-cell lymphoma; Treatment Outcome; Tumors; Veterinary colleges; Vincristine; Vincristine - therapeutic use
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0226357

Lymphoma is the most common hematopoietic tumour in dogs and is remarkably similar to the human disease. Tumour biomarker discovery is providing new tools for diagnostics and predicting therapeutic response and clinical outcome. MicroRNAs are small non-coding RNAs that participate in post-transcriptional gene regulation and their aberrant expression can impact genes involved in cancer. The aim of this study was to characterize microRNA expression in lymph nodes and plasma from dogs with multicentric B or T cell lymphoma compared to healthy control dogs. We further compared expression between lymph nodes and corresponding plasma samples and assessed changes in expression at relapse compared to time of diagnosis. Lastly, we investigated microRNAs for association with clinical outcome in patients treated with CHOP chemotherapy. A customized PCR array was utilized to profile 38 canine target microRNAs. Quantification was performed using real time RT-qPCR and relative expression was determined by the delta-delta Ct method. In lymph nodes, there were 16 microRNAs with significantly altered expression for B cell lymphoma and 9 for T cell lymphoma. In plasma, there were 15 microRNAs altered for B cell lymphoma and 3 for T cell lymphoma. The majority of microRNAs did not have correlated expression between lymph node and plasma and only 8 microRNAs were significantly different between diagnosis and relapse. For B cell lymphoma, 8 microRNAs had differential expression in the non-remission group compared to dogs that completed CHOP in complete remission. Four of these microRNAs were also altered in patients that died prior to one-year. Kaplan-Meier survival curves for high versus low microRNA expression revealed that 10 microRNAs were correlated with progression-free survival and 3 with overall survival. This study highlights microRNAs of interest for canine multicentric lymphoma. Future goals include development of microRNA panels that may be useful as biomarkers with the intent to provide improved outcome prediction to veterinary cancer patients.